# Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

> **NCT03679754** · PHASE1 · COMPLETED · sponsor: **Alaunos Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Ad-RTS-hIL-12
- **DRUG:** veledimex

## Key facts

- **NCT ID:** NCT03679754
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2019-04-02
- **Final completion:** 2021-01-19
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03679754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03679754, "Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03679754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*